There was a major breakthrough for scientists from Australia who designed a new blood test named “painHS” to detect chronic pain through color biomarkers.
There are numerous studies involving intestinal microbes like probiotics and its link with healthy intestines. But these host-microbe in other organs like the lungs were poorly understood, which led to inflammation.
Studies have shown that omega-3 fatty acids regulate the functioning of proteins and keeps inflammation totally under control. Still more research work is going on, in order to connect fish and cardiovascular systems in a beneficial manner.
A research study led by Professor Marina Botto, from the Department of Medicine in Imperial College London, revealed that a particular component of the immune system called C1q triggers an alarm when the body is attacked by a bacteria or virus and helps in coordinating the defense.
The problem with the common cold is that it isn’t just one virus. It’s a family of viruses that evolve so quickly no one can ever be fully immune to the cold, and developing a vaccine that can tackle all of the variations of the virus is impossible. But what if there were one way to block the ability of all cold viruses from replicating—thereby fending off the sneezing, sore throat and general misery that they cause?
When it comes to manufacturing CAR T drugs (personalized treatments engineering immune cells to destroy cancer cells of patients) speed is of utmost importance. A new manufacturing site has been decided upon by Gilead for Yescarta, its CAR-T therapy at a Netherlands airport.
According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms
Nation’s first approved personalized cellular therapy now available for second indication
Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.